Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine

DNA cytosine methylation plays a considerable role in normal development, gene regulation, and carcinogenesis. Hypermethylation of the promoters of some tumor suppressor genes and the associated silencing of these genes often occur in certain cancer types. The reversal of this process by DNA methylation inhibitors is a promising new strategy for cancer therapy. In addition to the four well-characterized nucleoside analogue methylation inhibitors, 5-azacytidine, 5-aza-2′-deoxycytidine (5-Aza-CdR), 5-fluoro-2′-deoxycytidine, and zebularine, there is a growing list of non-nucleoside inhibitors. However, a systemic study comparing these potential demethylating agents has not been done. In this study, we examined three non-nucleoside demethylating agents, (−)-epigallocatechin-3-gallate, hydralazine, and procainamide, and compared their effects and potencies with 5-Aza-CdR, the most potent DNA methylation inhibitor. We found that 5-Aza-CdR is far more effective in DNA methylation inhibition as well as in reactivating genes, compared with non-nucleoside inhibitors.

[1]  D. Mittelman,et al.  Genome-wide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian cells. , 2004, Human molecular genetics.

[2]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[3]  T. Kubota,et al.  Inhibition of DNA methyltransferase by antisense oligodeoxynucleotide modifies cell characteristics in gastric cancer cell lines. , 2004, Oncology reports.

[4]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[5]  E. Li,et al.  Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting , 2004, Nature.

[6]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[7]  Nagi B. Kumar,et al.  Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. , 2004, Nutrition reviews.

[8]  Y. Surh,et al.  Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. , 2004, Toxicology letters.

[9]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[10]  Ni Ai,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. , 2003, Cancer research.

[11]  Manel Esteller,et al.  Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. , 2003, Cancer research.

[12]  A. M. Salazar,et al.  Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  K. Bair,et al.  Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. , 2003, The Journal of organic chemistry.

[14]  S. Sukumar,et al.  Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells , 2003, Cancer biology & therapy.

[15]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[16]  Zhiyong Zhang,et al.  Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. , 2003, Arthritis & Rheumatism.

[17]  P. Laird,et al.  Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.

[18]  Lei Zhou,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.

[19]  Peter A. Jones,et al.  Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). , 2002, Methods.

[20]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[21]  J. Herman,et al.  Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.

[22]  S. Piantadosi,et al.  Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. , 2001, Cancer research.

[23]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[24]  Peter A. Jones,et al.  The Role of DNA Methylation in Mammalian Epigenetics , 2001, Science.

[25]  R. Momparler,et al.  Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.

[26]  Rudolf Jaenisch,et al.  Synergism of Xist Rna, DNA Methylation, and Histone Hypoacetylation in Maintaining X Chromosome Inactivation , 2001, The Journal of cell biology.

[27]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[28]  M. Lübbert,et al.  DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.

[29]  Thierry Boon,et al.  DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter , 1999, Molecular and Cellular Biology.

[30]  P. Jones,et al.  The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. , 1998, Cancer research.

[31]  A. Monaco,et al.  Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. , 1997, Genomics.

[32]  M. Herlyn,et al.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.

[33]  V. Zagonel,et al.  5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. , 1993, Leukemia.

[34]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Richardson,et al.  Procainamide inhibits DNA methyltransferase in a human T cell line. , 1991, The Journal of rheumatology.

[36]  S. Hanash,et al.  N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide. , 1988, Arthritis and rheumatism.

[37]  S. Hanash,et al.  Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. , 1988, Journal of immunology.

[38]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.